Reata Pharmaceuticals Inc RETA:NASDAQ

Last Price$81.40NASDAQ Previous Close - Last Trade as of 1:00PM ET 11/26/21

Today's Change-3.45(4.07%)
Bid (Size)$81.55 (2)
Ask (Size)$81.60 (4)
Day Low / High$80.85 - 84.44
Volume197.5 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 11/26/2021

 

Reata Pharmaceuticals Inc ( NASDAQ )

Price: $81.40
Change: -3.45 (4.07%)
Volume: 197.5 K
1:00PM ET 11/26/2021
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $129.56
Change: -5.09 (3.78%)
Volume: 101.1 K
1:00PM ET 11/26/2021
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $39.30
Change: -2.38 (5.71%)
Volume: 271.4 K
1:00PM ET 11/26/2021
 
 

Apellis Pharmaceuticals Inc ( NASDAQ )

Price: $43.54
Change: -1.47 (3.27%)
Volume: 524.3 K
1:00PM ET 11/26/2021
 
 

Allakos Inc ( NASDAQ )

Price: $80.09
Change: -1.13 (1.39%)
Volume: 192.3 K
1:00PM ET 11/26/2021
 

Read more news Recent News

Reata Pharmaceuticals Secures FDA Fast Track Designation for Rare Genetic Disorder Treatment
4:47AM ET 11/19/2021 MT Newswires

Reata Pharmaceuticals (RETA) said Thursday the US Food and Drug Administration has granted fast track designation for omaveloxolone for the treatment of...

Sector Update: Health Care Stocks Climb Premarket Monday
9:08AM ET 11/08/2021 MT Newswires

Health care stocks were climbing premarket Monday. The Health Care SPDR (XLV) was 0.02% higher and the iShares NASDAQ Biotechnology Index (IBB) was...

Reata Pharmaceuticals Narrows Q3 Adjusted Net Loss; Collaboration Revenue Rises
7:31AM ET 11/08/2021 MT Newswires

Reata Pharmaceuticals (RETA) reported a narrower Q3 adjusted net loss Monday of $1.27 per share, compared with a net loss of $1.31 a year earlier. Analysts...

-- Earnings Flash (RETA) REATA PHARMACEUTICALS Posts Q3 Revenue $7.4M, vs. Street Est of $2.08M
6:40AM ET 11/08/2021 MT Newswires

...

Company Profile

Business DescriptionReata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX. View company web site for more details
Address5320 Legacy Drive
Plano, Texas 75024
Phone+1.972.865.2219
Number of Employees123
Recent SEC Filing11/15/20213
Chairman, President & Chief Executive OfficerJ. Warren Huff
Executive VP, Chief Operating & Financial OfficerManmeet Singh Soni
Chief Scientific Officer, SVP & Founding ScientistW. Christian Wigley
Chief Research & Development Officer, Executive VPColin J. Meyer

Company Highlights

Price Open$82.57
Previous Close$84.85
52 Week Range$76.34 - 160.41
Market Capitalization$2.6 B
Shares Outstanding31.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.75
Beta vs. S&P 500N/A
Revenue$53.6 M
Net Profit Margin-2,020.49%
Return on Equity-81.91%

Analyst Ratings as of 11/08/2021

Buy
8
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset